1b1j › Citations

Refined crystal structures of native human angiogenin and two active site variants: implications for the unique functional properties of an enzyme involved in neovascularisation during tumour growth.

Leonidas DD, Shapiro R, Allen SC, Subbarao GV, Veluraja K, Acharya KR
J Mol Biol 285 1209-33 (1999)
Related entries: 1b1e, 1b1i, 2ang

Cited: 55 times
EuropePMC logo PMID: 9918722

Abstract

Human angiogenin (Ang), an unusual member of the pancreatic RNase superfamily, is a potent inducer of angiogenesis in vivo. Its ribonucleolytic activity is weak (10(4) to 10(6)-fold lower than that of bovine RNase A), but nonetheless seems to be essential for biological function. Ang has been implicated in the establishment of a wide range of human tumours and has therefore emerged as an important target for the design of new anti-cancer compounds. We report high-resolution crystal structures for native Ang in two different forms (Pyr1 at 1.8 A and Met-1 at 2.0 A resolution) and for two active-site variants, K40Q and H13A, at 2.0 A resolution. The native structures, together with earlier mutational and biochemical data, provide a basis for understanding the unique functional properties of this molecule. The major structural features that underlie the weakness of angiogenin's RNase activity include: (i) the obstruction of the pyrimidine-binding site by Gln117; (ii) the existence of a hydrogen bond between Thr44 and Thr80 that further suppresses the effectiveness of the pyrimidine site; (iii) the absence of a counterpart for the His119-Asp121 hydrogen bond that potentiates catalysis in RNase A (the corresponding aspartate in Ang, Asp116, has been recruited to stabilise the blockage of the pyrimidine site); and (iv) the absence of any precise structural counterparts for two important purine-binding residues of RNase A. Analysis of the native structures has revealed details of the cell-binding region and nuclear localisation signal of Ang that are critical for angiogenicity. The cell-binding site differs dramatically from the corresponding regions of RNase A and two other homologues, eosinophil-derived neurotoxin and onconase, all of which lack angiogenic activity. Determination of the structures of the catalytically inactive variants K40Q and H13A has now allowed a rigorous assessment of the relationship between the ribonucleolytic and biological activities of Ang. No significant change outside the enzymatic active site was observed in K40Q, establishing that the loss of angiogenic activity for this derivative is directly attributable to disruption of the catalytic apparatus. The H13A structure shows some changes beyond the ribonucleolytic site, but sites involved in cell-binding and nuclear translocation are essentially unaffected by the amino acid replacement.

Articles - 1b1j mentioned but not cited (3)

  1. Membrane protein stability analyses by means of protein energy profiles in case of nephrogenic diabetes insipidus. Heinke F, Labudde D. Comput Math Methods Med 2012 790281 (2012)
  2. eProS--a database and toolbox for investigating protein sequence-structure-function relationships through energy profiles. Heinke F, Schildbach S, Stockmann D, Labudde D. Nucleic Acids Res 41 D320-6 (2013)
  3. Structure of angiogenin dimer bound to double-stranded RNA. Sievers K, Ficner R. Acta Crystallogr F Struct Biol Commun 78 330-337 (2022)


Reviews citing this publication (8)

  1. The eight human "canonical" ribonucleases: molecular diversity, catalytic properties, and special biological actions of the enzyme proteins. Sorrentino S. FEBS Lett 584 2194-2200 (2010)
  2. Three decades of research on angiogenin: a review and perspective. Sheng J, Xu Z. Acta Biochim Biophys Sin (Shanghai) 48 399-410 (2016)
  3. Mammalian antimicrobial proteins and peptides: overview on the RNase A superfamily members involved in innate host defence. Boix E, Nogués MV. Mol Biosyst 3 317-335 (2007)
  4. Human antimicrobial proteins effectors of innate immunity. Harder J, Gläser R, Schröder JM. J Endotoxin Res 13 317-338 (2007)
  5. Generation of 2',3'-Cyclic Phosphate-Containing RNAs as a Hidden Layer of the Transcriptome. Shigematsu M, Kawamura T, Kirino Y. Front Genet 9 562 (2018)
  6. Ribonucleases and their antitumor activity. Matousek J. Comp Biochem Physiol C Toxicol Pharmacol 129 175-191 (2001)
  7. New insights into the role of angiogenin in actin polymerization. Pyatibratov MG, Kostyukova AS. Int Rev Cell Mol Biol 295 175-198 (2012)
  8. Human and mouse angiogenins: Emerging insights and potential opportunities. Sultana MF, Abo H, Kawashima H. Front Microbiol 13 1022945 (2022)

Articles citing this publication (44)

  1. Extensive terminal and asymmetric processing of small RNAs from rRNAs, snoRNAs, snRNAs, and tRNAs. Li Z, Ender C, Meister G, Moore PS, Chang Y, John B. Nucleic Acids Res 40 6787-6799 (2012)
  2. A cytotoxic ribonuclease which specifically cleaves four isoaccepting arginine tRNAs at their anticodon loops. Tomita K, Ogawa T, Uozumi T, Watanabe K, Masaki H. Proc Natl Acad Sci U S A 97 8278-8283 (2000)
  3. Prediction of protein deamidation rates from primary and three-dimensional structure. Robinson NE, Robinson AB. Proc Natl Acad Sci U S A 98 4367-4372 (2001)
  4. A small-molecule inhibitor of the ribonucleolytic activity of human angiogenin that possesses antitumor activity. Kao RY, Jenkins JL, Olson KA, Key ME, Fett JW, Shapiro R. Proc Natl Acad Sci U S A 99 10066-10071 (2002)
  5. Evolutionarily conserved linkage between enzyme fold, flexibility, and catalysis. Ramanathan A, Agarwal PK. PLoS Biol 9 e1001193 (2011)
  6. A new role for angiogenin in neurite growth and pathfinding: implications for amyotrophic lateral sclerosis. Subramanian V, Feng Y. Hum Mol Genet 16 1445-1453 (2007)
  7. Kaposi's sarcoma-associated herpesvirus upregulates angiogenin during infection of human dermal microvascular endothelial cells, which induces 45S rRNA synthesis, antiapoptosis, cell proliferation, migration, and angiogenesis. Sadagopan S, Sharma-Walia N, Veettil MV, Bottero V, Levine R, Vart RJ, Chandran B. J Virol 83 3342-3364 (2009)
  8. Cryo-EM structures of the SARS-CoV-2 endoribonuclease Nsp15 reveal insight into nuclease specificity and dynamics. Pillon MC, Frazier MN, Dillard LB, Williams JG, Kocaman S, Krahn JM, Perera L, Hayne CK, Gordon J, Stewart ZD, Sobhany M, Deterding LJ, Hsu AL, Dandey VP, Borgnia MJ, Stanley RE. Nat Commun 12 636 (2021)
  9. Subtle functional collective motions in pancreatic-like ribonucleases: from ribonuclease A to angiogenin. Merlino A, Vitagliano L, Ceruso MA, Mazzarella L. Proteins 53 101-110 (2003)
  10. Virtual screening to enrich hit lists from high-throughput screening: a case study on small-molecule inhibitors of angiogenin. Jenkins JL, Jenkins JL, Kao RY, Shapiro R. Proteins 50 81-93 (2003)
  11. Analysis of the interactions of human ribonuclease inhibitor with angiogenin and ribonuclease A by mutagenesis: importance of inhibitor residues inside versus outside the C-terminal "hot spot". Shapiro R, Ruiz-Gutierrez M, Chen CZ. J Mol Biol 302 497-519 (2000)
  12. Prediction of functional loss of human angiogenin mutants associated with ALS by molecular dynamics simulations. Padhi AK, Jayaram B, Gomes J. Sci Rep 3 1225 (2013)
  13. Diversifying selection of the tumor-growth promoter angiogenin in primate evolution. Zhang J, Rosenberg HF. Mol Biol Evol 19 438-445 (2002)
  14. Mechanisms of loss of functions of human angiogenin variants implicated in amyotrophic lateral sclerosis. Padhi AK, Kumar H, Vasaikar SV, Jayaram B, Gomes J. PLoS One 7 e32479 (2012)
  15. High-level expression of three members of the murine angiogenin family in Escherichia coli and purification of the recombinant proteins. Holloway DE, Hares MC, Shapiro R, Subramanian V, Acharya KR. Protein Expr Purif 22 307-317 (2001)
  16. Genetic selection for critical residues in ribonucleases. Smith BD, Raines RT. J Mol Biol 362 459-478 (2006)
  17. Enzymatic and structural characterisation of amphinase, a novel cytotoxic ribonuclease from Rana pipiens oocytes. Singh UP, Ardelt W, Saxena SK, Holloway DE, Vidunas E, Lee HS, Saxena A, Shogen K, Acharya KR. J Mol Biol 371 93-111 (2007)
  18. Ribonuclease A homologues of the zebrafish: polymorphism, crystal structures of two representatives and their evolutionary implications. Kazakou K, Holloway DE, Prior SH, Subramanian V, Acharya KR. J Mol Biol 380 206-222 (2008)
  19. Structural insights into human angiogenin variants implicated in Parkinson's disease and Amyotrophic Lateral Sclerosis. Bradshaw WJ, Rehman S, Pham TT, Thiyagarajan N, Lee RL, Subramanian V, Acharya KR. Sci Rep 7 41996 (2017)
  20. The crystal structure of human angiogenin in complex with an antitumor neutralizing antibody. Chavali GB, Papageorgiou AC, Olson KA, Fett JW, Hu Gf, Shapiro R, Acharya KR. Structure 11 875-885 (2003)
  21. Binding of phosphate and pyrophosphate ions at the active site of human angiogenin as revealed by X-ray crystallography. Leonidas DD, Chavali GB, Jardine AM, Li S, Shapiro R, Acharya KR. Protein Sci 10 1669-1676 (2001)
  22. Fast prediction of deleterious angiogenin mutations causing amyotrophic lateral sclerosis. Padhi AK, Vasaikar SV, Jayaram B, Gomes J. FEBS Lett 587 1762-1766 (2013)
  23. Novel angiogenin mutants with increased cytotoxicity enhance the depletion of pro-inflammatory macrophages and leukemia cells ex vivo. Cremer C, Braun H, Mladenov R, Schenke L, Cong X, Jost E, Brümmendorf TH, Fischer R, Carloni P, Barth S, Nachreiner T. Cancer Immunol Immunother 64 1575-1586 (2015)
  24. Structure of murine angiogenin: features of the substrate- and cell-binding regions and prospects for inhibitor-binding studies. Holloway DE, Chavali GB, Hares MC, Subramanian V, Acharya KR. Acta Crystallogr D Biol Crystallogr 61 1568-1578 (2005)
  25. Structural and functional implications of positive selection at the primate angiogenin gene. Osorio DS, Antunes A, Ramos MJ. BMC Evol Biol 7 167 (2007)
  26. In silico screening of mutational effects on enzyme-proteic inhibitor affinity: a docking-based approach. Dell'Orco D, De Benedetti PG, Fanelli F. BMC Struct Biol 7 37 (2007)
  27. Protein-water interactions in ribonuclease A and angiogenin: a molecular dynamics study. Sanjeev BS, Vishveshwara S. Proteins 55 915-923 (2004)
  28. Crystal structures of murine angiogenin-2 and -3-probing 'structure--function' relationships amongst angiogenin homologues. Iyer S, Holloway DE, Acharya KR. FEBS J 280 302-318 (2013)
  29. Inhibition of mammalian ribonucleases by endogenous adenosine dinucleotides. Kumar K, Jenkins JL, Jardine AM, Shapiro R. Biochem Biophys Res Commun 300 81-86 (2003)
  30. Evidence for Novel Action at the Cell-Binding Site of Human Angiogenin Revealed by Heteronuclear NMR Spectroscopy, in silico and in vivo Studies. Chatzileontiadou DSM, Tsika AC, Diamantopoulou Z, Delbé J, Badet J, Courty J, Skamnaki VT, Parmenopoulou V, Komiotis D, Hayes JM, Spyroulias GA, Leonidas DD. ChemMedChem 13 259-269 (2018)
  31. Letter The ammonium sulfate inhibition of human angiogenin. Chatzileontiadou DS, Tsirkone VG, Dossi K, Kassouni AG, Liggri PG, Kantsadi AL, Stravodimos GA, Balatsos NA, Skamnaki VT, Leonidas DD. FEBS Lett 590 3005-3018 (2016)
  32. Computer modeling of human angiogenin-dinucleotide substrate interaction. Madhusudhan MS, Vishveshwara S. Proteins 42 125-135 (2001)
  33. RNase A Treatment Interferes With Leukocyte Recruitment, Neutrophil Extracellular Trap Formation, and Angiogenesis in Ischemic Muscle Tissue. Lasch M, Kumaraswami K, Nasiscionyte S, Kircher S, van den Heuvel D, Meister S, Ishikawa-Ankerhold H, Deindl E. Front Physiol 11 576736 (2020)
  34. A reinforced merging methodology for mapping unique peptide motifs in members of protein families. Chang HT, Pai TW, Fan TC, Su BH, Wu PC, Tang CY, Chang CT, Liu SH, Chang MD. BMC Bioinformatics 7 38 (2006)
  35. Angiogenin mutations in Hungarian patients with amyotrophic lateral sclerosis: Clinical, genetic, computational, and functional analyses. Tripolszki K, Danis J, Padhi AK, Gomes J, Bozó R, Nagy ZF, Nagy D, Klivényi P, Engelhardt JI, Széll M. Brain Behav 9 e01293 (2019)
  36. Computer modeling and molecular dynamics simulations of ligand bound complexes of bovine angiogenin: dinucleotide topology at the active site of RNase a family proteins. Madhusudhan MS, Sanjeev BS, Vishveshwara S. Proteins 45 30-39 (2001)
  37. Crystal structure of human angiogenin with an engineered loop exhibits conformational flexibility at the functional regions of the molecule. Thiyagarajan N, Acharya KR. FEBS Open Bio 3 65-70 (2013)
  38. Dynamics of the native and the ligand-bound structures of eosinophil cationic protein: network of hydrogen bonds at the catalytic site. Sanjeev BS, Vishveshwara S. J Biomol Struct Dyn 22 657-672 (2005)
  39. Rare Angiogenin and Ribonuclease 4 variants associated with amyotrophic lateral sclerosis exhibit loss-of-function: a comprehensive in silico study. Padhi AK, Narain P, Gomes J. Metab Brain Dis 34 1661-1677 (2019)
  40. Structural basis of substrate specificity in porcine RNase 4. Liang S, Acharya KR. FEBS J 283 912-928 (2016)
  41. ANGDelMut - a web-based tool for predicting and analyzing functional loss mechanisms of amyotrophic lateral sclerosis-associated angiogenin mutations. Padhi AK, Vasaikar SV, Jayaram B, Gomes J. F1000Res 2 227 (2013)
  42. NMR study of Met-1 human Angiogenin: (1)H, (13)C, (15)N backbone and side-chain resonance assignment. Tsika AC, Chatzileontiadou DS, Leonidas DD, Spyroulias GA. Biomol NMR Assign 10 379-383 (2016)
  43. Conformational exchange divergence along the evolutionary pathway of eosinophil-associated ribonucleases. Bernard DN, Narayanan C, Hempel T, Bafna K, Bhojane PP, Létourneau M, Howell EE, Agarwal PK, Doucet N. Structure 31 329-342.e4 (2023)
  44. Protective Effects of Recombinant Human Angiogenin in Keratinocytes: New Insights on Oxidative Stress Response Mediated by RNases. Culurciello R, Bosso A, Troisi R, Barrella V, Di Nardo I, Borriello M, Gaglione R, Pistorio V, Aceto S, Cafaro V, Notomista E, Sica F, Arciello A, Pizzo E. Int J Mol Sci 23 8781 (2022)


Quick links